Companies › AMO Pharma
1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tideglusib Glycogen synthase kinase-3 beta inhibitor | GSK3B | Phase 2 | Congenital Myotonic Dystrophy; Arrhythmogenic Cardiomyopathy | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05004129 | Tideglusib | Phase 2 | Congenital Myotonic Dystrophy | Neurology | Dec 2026 |
| NCT06174220 | Tideglusib | Phase 2 | Arrhythmogenic Cardiomyopathy | Cardiovascular | Feb 2027 |
Ever Neuro Pharma Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) Translational Sciences Edgewise Therapeutics CSPC Mingfule Pharmaceutical (Guangzhou)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.